4,207 Shares in Incyte Co. (NASDAQ:INCY) Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new position in shares of Incyte Co. (NASDAQ:INCY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,207 shares of the biopharmaceutical company’s stock, valued at approximately $264,000.

A number of other large investors have also recently made changes to their positions in the company. CWM LLC lifted its holdings in Incyte by 85.2% during the 3rd quarter. CWM LLC now owns 5,129 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 2,360 shares in the last quarter. Czech National Bank lifted its holdings in Incyte by 48.3% during the 3rd quarter. Czech National Bank now owns 32,507 shares of the biopharmaceutical company’s stock valued at $1,878,000 after buying an additional 10,588 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in Incyte by 12.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,009 shares of the biopharmaceutical company’s stock valued at $1,156,000 after buying an additional 2,197 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Incyte by 5.8% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 106,964 shares of the biopharmaceutical company’s stock valued at $6,179,000 after buying an additional 5,900 shares in the last quarter. Finally, Toews Corp ADV bought a new stake in Incyte during the 3rd quarter valued at about $774,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on INCY shares. Cantor Fitzgerald started coverage on shares of Incyte in a report on Tuesday, April 23rd. They set a “neutral” rating for the company. Stifel Nicolaus boosted their price target on shares of Incyte from $67.00 to $68.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. JMP Securities lowered shares of Incyte from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 14th. Citigroup reduced their price target on shares of Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a report on Wednesday, February 14th. Finally, Oppenheimer reduced their price target on shares of Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a report on Wednesday. Nine research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Incyte has an average rating of “Moderate Buy” and a consensus target price of $75.50.

Incyte Stock Up 1.0 %

NASDAQ:INCY opened at $51.68 on Friday. The company has a market cap of $11.60 billion, a PE ratio of 19.50, a P/E/G ratio of 1.18 and a beta of 0.65. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $75.74. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $56.78 and its two-hundred day moving average is $57.70.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.09). The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Incyte had a net margin of 16.17% and a return on equity of 12.56%. The firm’s revenue was up 9.3% on a year-over-year basis. During the same period last year, the company earned $0.44 earnings per share. Analysts anticipate that Incyte Co. will post 3.84 EPS for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.